World's first generic to leading GnRH analogue with controlled release
Xbrane is pioneering high demand complex generics.
Latest News
-
Xbrane reaches commercial breakthrough with the first batches of Spherotide valued at SEK 7 million
Read more >> -
Xbrane Biopharma AB (publ) releases interim report for the period April - June 2016
Read more >> -
Xbrane Biopharma AB: Oxford Nanopore Technologies licenses Xbrane Biopharma's protein production technology
Read more >> -
Xbrane Biopharma AB (publ) publishes shareholder letter
Read more >>
OUTPERFORMING INDUSTRY STANDARDS BY DEVELOPING BIOSIMILARS WITH NEXT GENERATION TECHNOLOGY
Enabling access to critical medication for life critical diseases
Events
-
07 Jun 2016
Xbrane attending Jefferies Healthcare conference 7-10 June in New York
Read more >> -
06 Jun 2016
Xbrane attending Bio International 6-9 June in San Francisco
Read more >> -
25 May 2016
Xbrane presenting at "Nasdaq and Aktiespararna investerarkväll” 25 May in Stockholm
Read more >> -
18 Apr 2016
Xbrane attending China Bio 18-19 May in Suzhou
Read more >> -
10 May 2016
Xbrane attending BioEquity 10-11 May in Copenhagen
Read more >> -
02 May 2016
Xbrane presenting at Aktiespararna aktiedag 2 May at Operaterassen in Stockholm
Read more >> -
04 Apr 2016
Xbrane attending BioEurope 4-6 April in Stockholm
Read more >>
Press Releases
Xbrane Biopharma AB : Första milstolpen i kommersialiseringen av Xbranes Ranibizumab biosimilar Xlucane tillsammans med partner i Iran är uppnådd
Pressmeddelande &nb (…)
Press Releases
Xbrane Biopharma presenterar vid Vator Securities Unicorn Summit
2016-02-16 Vator Securities Unicorn Summit är en kapitalmarknadsdag med några av de mest intressanta svenska Life Science-bolagen. Eventet anordnas den 9 mars 2016 på IVA i Stockholm, med start klockan 15:00. Xbrane Biopharma är ett av fem utvalda bolag som ska presentera under eftermiddagen. För (…)
